Vet World   Vol.18   June-2025  Article - 30 

Establishment and molecular characterization of novel luminal A and luminal B canine mammary cancer cell lines for comparative oncology

Juthathip Jurutha¹ , Yanika Piyasanti¹, Kornkanok Sritabtim¹, Suparat Chaipipat¹ , Kannika Siripattarapravat^1,2 , Sukumal Prukudom^1,3 , Usuma Jermnak⁴ , Rungthiwa Sinsiri¹, Kakanang Wongsuppabut¹, Charuwan Wongsali¹, Nutawan Niyatiwatchanchai⁵ , Wijit Sutthiprapa⁵ , Napachanok Swainson⁶ , and Wachiraphan Supsavhad^1,2

Background and Aim: Canine mammary cancer (CMC) is the most frequently diagnosed malignancy in female dogs, sharing significant pathological and molecular similarities with human breast cancer (HBC). Despite the availability of various CMC cell lines, most represent triple-negative or epidermal growth factor receptor 2 (ErbB2)-enriched subtypes, which limit research on hormone receptor-positive cancers. This study aimed to establish and characterize novel CMC cell lines representing luminal A and B subtypes.

Materials and Methods: Between 2020 and 2021, 31 canine mammary tumors (CMTs) were collected from clinical cases. Tumor tissues were processed for primary culture, and two cell lines – CMGT_071020 and CMGT_180321 – were successfully established. Immunohistochemistry (IHC) was used to assess expression of estrogen receptor alpha (ERα), progesterone receptor (PR), ErbB2, Ki-67, vimentin, and multi-cytokeratin. Functional assays (wound-healing and transwell migration) assessed metastatic behavior. Gene expression (EGFR, TP53, Bcl-2, PTEN, SNAIL, N-cadherin, and E-cadherin) was analyzed using reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR). Cell line authentication was confirmed through short tandem repeat (STR) profiling and mycoplasma testing.

Results: The CMGT_071020 (luminal B) and CMGT_180321 (luminal A) cell lines were derived from malignant epithelial tumors and maintained stable growth over 30 passages. IHC confirmed molecular subtype classifications. CMGT_071020 exhibited a fibroblast-like morphology, a high Ki-67 index (67%), and superior migratory capacity compared to CMGT_180321 and the commercial ErbB2-enriched REM134 cell line. E-cadherin expression was significantly elevated in CMGT_071020 (p < 0.05), whereas the expression levels of other genes were comparable. STR analysis verified their genetic uniqueness, and both lines were free from mycoplasma contamination.

Conclusion: This study successfully established and characterized two novel hormone receptor-positive CMC cell lines, representing luminal A and luminal B subtypes. The CMGT_071020 line exhibited higher metastatic potential, offering a promising model for aggressive hormone-responsive CMC. These cell lines provide valuable tools for comparative oncology and may facilitate subtype-specific therapeutic research.

Keywords: canine mammary cancer, cell line establishment, comparative oncology, immunohistochemistry, luminal A, luminal B, metastasis, molecular subtype, reverse transcription quantitative real-time polymerase chain reaction.

How to cite this article: Jurutha J, Piyasanti Y, Sritabtim K, Chaipipat S, Siripattarapravat K, Prukudom S, Jermnak U, Sinsiri R, Wongsuppabut K, Wongsali C, Niyatiwatchanchai N, Sutthiprapa W, Swainson N, and Supsavhad W (2025) Establishment and molecular characterization of novel luminal A and luminal B canine mammary cancer cell lines for comparative oncology, Veterinary World, 18(6): 1725-1740.

Received: 04-12-2025   Accepted: 23-05-2025   Published online: 26-06-2025

Corresponding author: Wachiraphan Supsavhad    E-mail: wachiraphan.s@ku.th

DOI: 10.14202/vetworld.2025.1725-1740

Copyright: Jurutha, et al. This article is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.